Adaptive Biotechnologies Corp 8-K

What Happened

• On February 5, 2026, Adaptive Biotechnologies Corporation announced it issued a press release reporting the company's financial results for the quarter and fiscal year ended December 31, 2025. The announcement was furnished in an SEC Form 8‑K under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: February 5, 2026.
• Reporting period: quarter and fiscal year ended December 31, 2025.
• Exhibit included: Press Release dated February 5, 2026 (Exhibit 99.1) is attached and incorporated by reference.
• Technical exhibit: Cover Page Interactive Data File included as Exhibit 104 (Inline XBRL).
• Form 8‑K signed by Kyle Piskel, Chief Financial Officer.

Why It Matters

• The filing notifies investors that Adaptive has publicly released its Q4 and full-year 2025 financial results; investors should review the attached press release for revenue, profit/loss, cash position, and any management commentary or guidance.
• Because the 8‑K itself does not state financial figures, the press release (Exhibit 99.1) is the primary source for material metrics that may affect the company’s stock and investor decisions.